Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 31: Where does beta-oxidation of fatty acids occur?

A. Mitochondria (Correct Answer)
B. Peroxisomes
C. Cytosol
D. Golgi apparatus

Explanation: **Explanation:** **Beta-oxidation of fatty acids** is the primary metabolic pathway for the breakdown of long-chain fatty acids to generate energy in the form of ATP. **Why Mitochondria is correct:** The majority of fatty acid oxidation occurs within the **mitochondrial matrix**. After fatty acids are activated in the cytosol to Fatty Acyl-CoA, they are transported across the inner mitochondrial membrane via the **Carnitine Shuttle** (the rate-limiting step). Once inside the matrix, the fatty acid undergoes a four-step cyclic process (oxidation, hydration, oxidation, and thiolysis), yielding Acetyl-CoA, NADH, and FADH₂. Acetyl-CoA then enters the TCA cycle for further energy production. **Why other options are incorrect:** * **Peroxisomes:** While very-long-chain fatty acids (VLCFA, >22 carbons) begin oxidation in peroxisomes, the process is incomplete and must be finished in the mitochondria. * **Cytosol:** This is the site for fatty acid **synthesis** (lipogenesis), not oxidation. The separation of these pathways (synthesis in cytosol vs. oxidation in mitochondria) prevents a futile cycle. * **Golgi apparatus:** This organelle is involved in the modification, sorting, and packaging of proteins and lipids, but not their catabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Carnitine Palmitoyltransferase-I (CPT-I). * **Inhibitor:** Malonyl-CoA (an intermediate of fatty acid synthesis) inhibits CPT-I, preventing simultaneous synthesis and breakdown. * **Clinical Correlation:** **Zellweger Syndrome** is a peroxisomal biogenesis disorder leading to the accumulation of VLCFAs. **MCAD deficiency** is the most common inborn error of beta-oxidation, presenting with hypoketotic hypoglycemia.

Question 32: Fatty acid oxidation occurs in which cellular compartment?

A. Cytoplasm
B. Microsomes
C. Mitochondria (Correct Answer)
D. All of the above

Explanation: ### Explanation **Correct Answer: C. Mitochondria** **Underlying Medical Concept:** Fatty acid oxidation (specifically **Beta-oxidation**) is the primary process by which fatty acids are broken down to generate energy (ATP). This process occurs within the **mitochondrial matrix**. Long-chain fatty acids are transported from the cytosol into the mitochondria via the **Carnitine Shuttle** (the rate-limiting step). Once inside, the fatty acids undergo a repetitive four-step cycle (oxidation, hydration, oxidation, and thiolysis) to produce Acetyl-CoA, NADH, and FADH₂, which then enter the TCA cycle and Electron Transport Chain to yield energy. **Analysis of Incorrect Options:** * **A. Cytoplasm:** While fatty acid **synthesis** (Lipogenesis) occurs in the cytoplasm, oxidation does not. The cytoplasm is the site for the activation of fatty acids into Fatty Acyl-CoA, but the actual breakdown happens inside the mitochondria. * **B. Microsomes:** Microsomes (Endoplasmic Reticulum) are involved in the **elongation** of fatty acid chains and **omega-oxidation** (a minor pathway), but they are not the site for the primary beta-oxidation pathway. * **D. All of the above:** This is incorrect because the enzymes for the beta-oxidation spiral are localized specifically within the mitochondrial matrix. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** Carnitine Palmitoyltransferase-I (CPT-I). * **Inhibitor:** Malonyl-CoA (an intermediate of synthesis) inhibits CPT-I, preventing a futile cycle where synthesis and oxidation happen simultaneously. * **Alternative Sites:** **Very Long Chain Fatty Acids (VLCFA)** undergo initial oxidation in **Peroxisomes** (Zellweger Syndrome is a clinical correlation here). * **Energy Yield:** The complete oxidation of one molecule of **Palmitate (16C)** yields a net of **106 ATP**.

Question 33: Which lipoprotein carries the highest amount of cholesterol?

A. High-density lipoprotein (HDL)
B. Low-density lipoprotein (LDL) (Correct Answer)
C. Very-low-density lipoprotein (VLDL)
D. Intermediate-density lipoprotein (IDL)

Explanation: **Explanation:** The correct answer is **Low-density lipoprotein (LDL)**. Lipoproteins are classified based on their density and composition of lipids (triacylglycerols, cholesterol, phospholipids) and proteins. **Why LDL is the correct answer:** LDL is the primary carrier of cholesterol in the blood, transporting it from the liver to peripheral tissues. It is derived from VLDL via IDL. As VLDL loses triglycerides through the action of lipoprotein lipase, the relative proportion of cholesterol increases. LDL contains approximately **50% cholesterol** (mostly cholesterol esters), making it the most cholesterol-rich lipoprotein. **Analysis of Incorrect Options:** * **HDL (High-density lipoprotein):** Known as "good cholesterol," it has the highest **protein** content (approx. 50%) but contains less total cholesterol than LDL. Its role is reverse cholesterol transport (periphery to liver). * **VLDL (Very-low-density lipoprotein):** This lipoprotein is primarily composed of **endogenous triglycerides** (approx. 50-60%). It carries lipids from the liver to the periphery. * **IDL (Intermediate-density lipoprotein):** A transient intermediate between VLDL and LDL; it contains roughly equal amounts of triglycerides and cholesterol. **High-Yield Clinical Pearls for NEET-PG:** * **Chylomicrons:** Carry the highest amount of **triglycerides** (90%) and are the least dense. * **Apolipoprotein B-100:** The primary structural protein found in VLDL, IDL, and LDL. * **Friedewald Equation:** Used to calculate LDL cholesterol: $LDL = Total\ Cholesterol – (HDL + TG/5)$. (Note: Not applicable if TG >400 mg/dL). * **Oxidized LDL:** The key factor in atherogenesis and foam cell formation in arterial walls.

Question 34: In chronic diabetics, why are the values of triglycerides (TG) and very-low-density lipoprotein (VLDL) elevated?

A. Increased activity of hepatic lipase
B. Increased peripheral function of LDL receptors
C. Increased activity of lipoprotein lipase and decreased activity of hormone-sensitive lipase
D. Increased activity of hormone-sensitive lipase and decreased lipoprotein lipase activity (Correct Answer)

Explanation: In diabetes mellitus, the primary metabolic driver is **insulin deficiency or resistance**. Insulin is the master regulator of lipid metabolism, and its absence leads to the following two-fold effect: ### 1. Why the Correct Answer is Right (Option D) * **Increased Hormone-Sensitive Lipase (HSL) activity:** Insulin normally inhibits HSL in adipose tissue. In diabetes, the lack of insulin "releases the brakes" on HSL, leading to excessive lipolysis. This floods the liver with **Free Fatty Acids (FFAs)**, which are then re-esterified into **Triglycerides (TG)** and packaged into **VLDL** for secretion. * **Decreased Lipoprotein Lipase (LPL) activity:** LPL is an insulin-dependent enzyme located on the capillary endothelium that clears VLDL and Chylomicrons from the blood. Low insulin levels result in reduced LPL synthesis, leading to impaired clearance of VLDL, further elevating plasma TG levels. ### 2. Why Other Options are Wrong * **Option A:** Hepatic lipase primarily converts IDL to LDL. Its increased activity would not explain the primary elevation of VLDL/TG seen in insulin deficiency. * **Option B:** Increased LDL receptor function would *lower* cholesterol levels; in diabetes, LDL receptor expression is actually decreased, contributing to hypercholesterolemia. * **Option C:** This is the exact opposite of the physiological state in diabetes. High LPL and low HSL are characteristics of the **fed state** (high insulin). ### 3. High-Yield Clinical Pearls for NEET-PG * **Type IV Hyperlipoproteinemia:** This is the most common lipid profile seen in uncontrolled diabetes (Elevated VLDL). * **The "Insulin-LPL" Connection:** Remember: **Insulin Stimulates LPL** (clears fat) but **Inhibits HSL** (prevents fat breakdown). * **Atherogenic Dyslipidemia:** Diabetics often present with the "Lipid Triad": High TG, Low HDL, and Small Dense LDL particles.

Question 35: Which of the following is true about Hypertriglyceridemia?

A. LDL receptor defect
B. Dysbetalipoprotenemia
C. Abetalipoprotenemia
D. None of the above (Correct Answer)

Explanation: **Explanation:** Hypertriglyceridemia refers to an elevated level of triglycerides in the blood, typically associated with abnormalities in **Chylomicrons** or **VLDL** (Very Low-Density Lipoproteins). **1. Why "None of the above" is correct:** The options provided describe conditions that either primarily involve cholesterol or represent a deficiency of lipids, rather than classic hypertriglyceridemia. True hypertriglyceridemia is seen in conditions like **Type I (Familial Chylomicronemia)**, **Type IV (Familial Hypertriglyceridemia)**, and **Type V Hyperlipoproteinemia**. **2. Analysis of Incorrect Options:** * **A. LDL receptor defect:** This is the hallmark of **Type IIa Hyperlipoproteinemia (Familial Hypercholesterolemia)**. It leads to isolated elevation of LDL and **cholesterol**, not triglycerides. * **B. Dysbetalipoproteinemia (Type III):** This is characterized by a defect in **Apo-E**, leading to the accumulation of IDL and Chylomicron remnants (Broad-beta disease). While it involves a rise in both cholesterol and triglycerides, it is specifically defined by "remnant" accumulation rather than pure hypertriglyceridemia. * **C. Abetalipoproteinemia:** This is a deficiency state caused by a mutation in the **MTP (Microsomal Triglyceride Transfer Protein)** gene. It results in a near-total absence of VLDL, LDL, and Chylomicrons, leading to *low* lipid levels, malabsorption, and acanthocytosis. **High-Yield Clinical Pearls for NEET-PG:** * **Pancreatitis Risk:** Severe hypertriglyceridemia (>1000 mg/dL) is a major risk factor for acute pancreatitis. * **Type I vs. Type IV:** Type I is due to **LPL (Lipoprotein Lipase)** or **Apo C-II** deficiency (creamy layer on top of plasma). Type IV is due to VLDL overproduction. * **Eruptive Xanthomas:** These are skin manifestations specifically associated with high triglyceride levels.

Question 36: Which of the following is not a polyunsaturated fatty acid (PUFA)?

A. Linoleic acid
B. Palmitoleic acid (Correct Answer)
C. Linolenic acid
D. Arachidonic acid

Explanation: ### Explanation The classification of fatty acids is based on the number of double bonds present in their hydrocarbon chain. **Polyunsaturated Fatty Acids (PUFAs)** are defined as fatty acids containing **two or more** double bonds. **Why Palmitoleic acid is the correct answer:** Palmitoleic acid is a **16-carbon** fatty acid with only **one** double bond located at the 9th carbon ($\omega$-7). Because it contains only a single double bond, it is classified as a **Monounsaturated Fatty Acid (MUFA)**, not a PUFA. **Analysis of Incorrect Options:** * **Linoleic acid (18:2, $\omega$-6):** Contains two double bonds. It is an essential PUFA and a precursor for arachidonic acid. * **Linolenic acid (18:3, $\omega$-3):** Contains three double bonds. It is an essential PUFA found in flaxseed and fish oils. * **Arachidonic acid (20:4, $\omega$-6):** Contains four double bonds. It is a semi-essential PUFA (essential if linoleic acid is deficient) and serves as the primary precursor for eicosanoids (prostaglandins, leukotrienes). **High-Yield NEET-PG Pearls:** 1. **Essential Fatty Acids:** Humans lack the enzymes ($\Delta^{12}$ and $\Delta^{15}$ desaturases) to introduce double bonds beyond the 9th carbon; hence, Linoleic and Linolenic acids must be obtained from the diet. 2. **Mnemonic for PUFAs:** "L-L-A" (Linoleic, Linolenic, Arachidonic). 3. **Oleic Acid (18:1, $\omega$-9):** The most common MUFA in the human diet (found in olive oil). 4. **Clinical Correlation:** Deficiency of essential PUFAs leads to **Phrynoderma** (toad skin), characterized by follicular hyperkeratosis.

Question 37: Which of the following enzymes is the most important enzyme for regulating lipogenesis?

A. Hydratase
B. Acetyl-CoA carboxylase (Correct Answer)
C. Enoyl reductase
D. Acetyl transacetylase

Explanation: **Explanation:** **Acetyl-CoA Carboxylase (ACC)** is the correct answer because it catalyzes the **rate-limiting and committed step** in fatty acid synthesis (lipogenesis). This enzyme converts Acetyl-CoA to Malonyl-CoA using biotin as a cofactor, ATP, and CO₂. Its regulatory importance stems from two mechanisms: 1. **Allosteric Regulation:** It is activated by Citrate (signaling high energy) and inhibited by Palmitoyl-CoA (feedback inhibition). 2. **Hormonal Regulation:** It is activated by Insulin (via dephosphorylation) and inhibited by Glucagon/Epinephrine (via phosphorylation by AMPK). Furthermore, Malonyl-CoA produced by ACC inhibits *Carnitine Palmitoyltransferase-I (CPT-I)*, preventing a futile cycle by stopping fatty acid oxidation while synthesis is active. **Why other options are incorrect:** * **Hydratase, Enoyl reductase, and Acetyl transacetylase** are all components of the **Fatty Acid Synthase (FAS) multienzyme complex**. While essential for the elongation of the fatty acid chain, they are not regulatory or rate-limiting steps. They function downstream of ACC once the committed Malonyl-CoA is already formed. **High-Yield Clinical Pearls for NEET-PG:** * **Cofactors for ACC:** Remember **ABC** (ATP, Biotin, and CO₂). * **Location:** Lipogenesis occurs in the **cytosol**, whereas beta-oxidation occurs in the mitochondria. * **Citrate Shuttle:** Acetyl-CoA leaves the mitochondria in the form of Citrate to participate in lipogenesis. * **Metformin Link:** Metformin activates AMPK, which phosphorylates and inhibits ACC, contributing to its lipid-lowering effects.

Question 38: Which of the following best describes phospholipids?

A. Simple lipids
B. Derived lipids
C. Complex lipids (Correct Answer)
D. None of the above

Explanation: **Explanation:** Lipids are broadly classified based on their chemical composition. **Phospholipids** are categorized as **Complex (or Compound) lipids** because, upon hydrolysis, they yield not only fatty acids and an alcohol but also additional groups—specifically a phosphoric acid residue and often a nitrogenous base. **Why Option C is Correct:** Complex lipids are esters of fatty acids containing groups in addition to an alcohol and a fatty acid. Phospholipids are the most abundant complex lipids. They are further divided into: 1. **Glycerophospholipids:** Alcohol is glycerol (e.g., Lecithin, Cephalin). 2. **Sphingophospholipids:** Alcohol is sphingosine (e.g., Sphingomyelin). **Why Other Options are Incorrect:** * **Option A (Simple lipids):** These are esters of fatty acids with various alcohols but contain no other groups. Examples include **Triacylglycerols (TAGs)** and **Waxes**. * **Option B (Derived lipids):** These are substances derived from the hydrolysis of simple and complex lipids that still possess the characteristics of lipids. Examples include **steroids (cholesterol)**, fatty acids, and lipid-soluble vitamins. **NEET-PG High-Yield Pearls:** * **Lecithin (Phosphatidylcholine)** is the most abundant phospholipid in the cell membrane. * **Dipalmitoyl lecithin (DPPC)** acts as a lung surfactant; its deficiency leads to **Respiratory Distress Syndrome (RDS)** in neonates. * **Sphingomyelin** is the only phospholipid that does not contain glycerol; it is found in the myelin sheath. * **Cardiolipin** is a unique phospholipid found in the inner mitochondrial membrane and is antigenic in syphilis (used in the VDRL test).

Question 39: A premature infant, when born, had low Apgar scores and was experiencing difficulty breathing. The NICU physician administered a lipid mixture that significantly reduced the respiratory distress. Besides proteins, what is a key component of this mixture?

A. Sphingomyelin
B. A mixture of gangliosides
C. Triacylglycerol
D. Phosphatidylcholine (Correct Answer)

Explanation: ### Explanation **Concept: Respiratory Distress Syndrome (RDS) and Lung Surfactant** The clinical presentation describes **Respiratory Distress Syndrome (RDS)**, commonly seen in premature infants due to a deficiency of **lung surfactant**. Surfactant is essential for reducing surface tension at the air-liquid interface of the alveoli, preventing their collapse during expiration (atelectasis). **Why Phosphatidylcholine is Correct:** Lung surfactant is composed of approximately 90% lipids and 10% proteins. The most abundant and functional lipid component is **Dipalmitoylphosphatidylcholine (DPPC)**, also known as **Lecithin**. It accounts for nearly 50-60% of the surfactant's weight. Its amphipathic nature allows it to form a monolayer that effectively lowers surface tension, facilitating lung expansion. **Analysis of Incorrect Options:** * **A. Sphingomyelin:** While present in amniotic fluid, its concentration remains relatively constant during pregnancy. It is used as a reference point in the **L/S ratio** (Lecithin/Sphingomyelin ratio) to assess fetal lung maturity, but it is not the active component that reduces surface tension. * **B. Gangliosides:** These are complex glycosphingolipids primarily found in the gray matter of the brain and cell membranes for signaling; they play no role in lung mechanics. * **C. Triacylglycerol:** These are storage lipids found in adipose tissue. They do not possess the structural properties required to act as surfactants. **High-Yield Clinical Pearls for NEET-PG:** * **L/S Ratio:** A ratio of **>2.0** in amniotic fluid indicates mature fetal lungs. * **Type II Pneumocytes:** These are the specialized alveolar cells responsible for the synthesis and secretion of surfactant. * **Lamellar Bodies:** Surfactant is stored in these intracellular organelles before being secreted via exocytosis. * **Glucocorticoids:** Administered to mothers in preterm labor to accelerate surfactant production by stimulating the maturation of Type II pneumocytes.

Question 40: What is true about the lecithin-sphingomyelin ratio in amniotic fluid?

A. Concentration of lecithin and sphingomyelin in amniotic fluid are equal before 34 weeks. (Correct Answer)
B. Concentration of lecithin is greater than sphingomyelin in amniotic fluid before 34 weeks.
C. After 32 to 34 weeks, the concentration of sphingomyelin relative to lecithin begins to rise.
D. There is an increased risk of Respiratory Distress Syndrome if the L/S ratio is less than 2.

Explanation: ### Explanation: Lecithin-Sphingomyelin (L/S) Ratio The **L/S ratio** is a crucial biochemical marker used to assess **fetal lung maturity**. It measures the concentration of surfactants in the amniotic fluid. **1. Why Option A is Correct:** Until approximately **32 to 34 weeks** of gestation, the concentrations of lecithin (dipalmitoylphosphatidylcholine) and sphingomyelin are roughly **equal**. Lecithin is the primary functional component of pulmonary surfactant, while sphingomyelin is a non-surfactant membrane lipid that remains relatively constant throughout pregnancy. **2. Analysis of Incorrect Options:** * **Option B:** Before 34 weeks, lecithin is not greater; the two are equal. It is only after 34 weeks that lecithin production surges due to the maturation of Type II pneumocytes. * **Option C:** After 32–34 weeks, the concentration of **lecithin rises sharply**, while sphingomyelin remains stable or decreases slightly. Therefore, the ratio increases, not the relative concentration of sphingomyelin. * **Option D:** While a ratio of **<2.0** indeed indicates an increased risk of Respiratory Distress Syndrome (RDS), the question asks for the "true" statement regarding the physiological trend. In many standardized exams (including NEET-PG), Option A is the classic physiological fact taught regarding the pre-34-week baseline. *(Note: While D is clinically significant, A describes the fundamental biochemical trend).* **3. High-Yield Clinical Pearls for NEET-PG:** * **L/S Ratio > 2.0:** Indicates mature lungs and a low risk of RDS. * **L/S Ratio < 1.5:** Indicates a high risk of RDS. * **Diabetes Mellitus:** In pregnancies complicated by maternal diabetes, RDS can occur even with an L/S ratio > 2.0 (delayed functional maturity). * **Phosphatidylglycerol (PG):** Its presence in amniotic fluid is the most reliable indicator of lung maturity, especially in diabetic mothers. * **Glucocorticoids:** Administered to the mother (e.g., Betamethasone) to accelerate surfactant production by inducing enzymes in Type II pneumocytes.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free